Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3907 |
| Name | lung squamous cell carcinoma |
| Definition | A non-small cell lung carcinoma that has_material_basis_in the squamous cell. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung squamous cell carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| FGFR1 amp | Ponatinib | lung squamous cell carcinoma | sensitive | detail... |
| PTEN loss | AZD8186 | lung squamous cell carcinoma | predicted - sensitive | detail... |
| FGFR1 amp | Dovitinib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA over exp | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA E545K | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA H1047R | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA over exp | Dactolisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA E545K | Dactolisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA H1047R | Dactolisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA H1047R | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA E545K | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA over exp | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
| FGFR1 amp | RO4987655 | lung squamous cell carcinoma | no benefit | detail... |
| FGFR1 amp | RO5126766 | lung squamous cell carcinoma | no benefit | detail... |
| FGFR1 amp | Selumetinib | lung squamous cell carcinoma | no benefit | detail... |
| HRAS Q61L | Selumetinib | lung squamous cell carcinoma | sensitive | detail... |
| HRAS Q61L | Buparlisib | lung squamous cell carcinoma | no benefit | detail... |
| HRAS Q61L | Everolimus + Selumetinib | lung squamous cell carcinoma | sensitive | detail... |
| HRAS Q61L | Binimetinib + Everolimus | lung squamous cell carcinoma | sensitive | detail... |
| HRAS Q61L | AZD8055 + Binimetinib | lung squamous cell carcinoma | sensitive | detail... |
| FGFR1 amp | Infigratinib | lung squamous cell carcinoma | sensitive | detail... |
| PTEN negative | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
| FGFR1 amp | Buparlisib + Fexagratinib | lung squamous cell carcinoma | sensitive | detail... |
| FGFR3 positive | Rogaratinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| FGFR1 amp | Fexagratinib | lung squamous cell carcinoma | no benefit | detail... |
| PTEN loss | Buparlisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA amp | Buparlisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA act mut | Buparlisib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| PIK3CA E545K PIK3CA amp | Buparlisib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| PIK3CA E542K PIK3CA amp | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA E545K PTEN loss | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA act mut | Alpelisib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| PIK3CA E542K PIK3CA amp | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA E542K PTEN loss | Alpelisib | lung squamous cell carcinoma | sensitive | detail... |
| CDKN2A loss PIK3CA act mut | Buparlisib + Palbociclib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| CDKN2A loss PIK3CA E545K PIK3CA amp | Buparlisib + Palbociclib | lung squamous cell carcinoma | sensitive | detail... |
| CDKN2A loss PIK3CA E542K PTEN loss | Buparlisib + Palbociclib | lung squamous cell carcinoma | sensitive | detail... |
| CDKN2A loss PIK3CA E542K PIK3CA amp | Buparlisib + Palbociclib | lung squamous cell carcinoma | sensitive | detail... |
| FGFR1 amp | Zoligratinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| PIK3CA mutant | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA E545K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA E542K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA H1047R | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA N345K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA E453K | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA G1049R | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA M1043I | Taselisib | lung squamous cell carcinoma | no benefit | detail... |
| CDKN2A loss | Palbociclib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| PIK3CA mutant | Capivasertib | lung squamous cell carcinoma | no benefit | detail... |
| PIK3CA amp | Capivasertib | lung squamous cell carcinoma | no benefit | detail... |
| PTEN loss | Capivasertib | lung squamous cell carcinoma | no benefit | detail... |
| FGFR1 amp | Carboplatin + GSK3052230 + Paclitaxel | lung squamous cell carcinoma | predicted - sensitive | detail... |
| FGFR1 over exp | Rogaratinib | lung squamous cell carcinoma | no benefit | detail... |
| FGFR3 over exp | Rogaratinib | lung squamous cell carcinoma | no benefit | detail... |
| FGFR2 over exp | Rogaratinib | lung squamous cell carcinoma | no benefit | detail... |
| EML4 - ALK | Crizotinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| EML4 - ALK | Brigatinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| EML4 - ALK ALK G1202R | Brigatinib | lung squamous cell carcinoma | predicted - resistant | detail... |
| EML4 - ALK ALK G1202R | Lorlatinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| EML4 - ALK | Alectinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| PIK3CA E542K PTEN loss | Buparlisib | lung squamous cell carcinoma | sensitive | detail... |
| PTEN loss | unspecified PD-1 antibody | lung squamous cell carcinoma | predicted - resistant | detail... |
| FGFR3 S249C | Erdafitinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| FGFR3 S249C | R3-altibody | lung squamous cell carcinoma | sensitive | detail... |
| BRAF V600E IDH1 R132C | Dabrafenib + Trametinib | lung squamous cell carcinoma | predicted - sensitive | detail... |
| HRAS G12S | Cisplatin + Pemetrexed Disodium + Trametinib | lung squamous cell carcinoma | sensitive | detail... |
| HRAS G12S | Buparlisib + Carboplatin + Paclitaxel | lung squamous cell carcinoma | sensitive | detail... |
| PIK3CA E542K | Buparlisib + Carboplatin + Paclitaxel | lung squamous cell carcinoma | sensitive | detail... |
| PTEN Q245* | Buparlisib + Carboplatin + Paclitaxel | lung squamous cell carcinoma | sensitive | detail... |
| PTEN Q245* | Carboplatin + Paclitaxel + Vistusertib | lung squamous cell carcinoma | sensitive | detail... |
| CDKN2A S12* PIK3CA E542K | Carboplatin + Paclitaxel + Palbociclib | lung squamous cell carcinoma | sensitive | detail... |
| CDKN2A D74Tfs*72 | Carboplatin + Paclitaxel + Palbociclib | lung squamous cell carcinoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
| NCT01737502 | Phase Ib/II | Auranofin + Sirolimus | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Completed | USA | 0 |
| NCT01741727 | Phase II | Depatuxizumab mafodotin | A Study of ABT-414 in Subjects With Solid Tumors | Completed | USA | CAN | 0 |
| NCT01820325 | Phase II | Buparlisib | Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | Terminated | USA | ITA | ESP | DEU | CAN | 0 |
| NCT01877811 | Phase Ib/II | RXDX-105 | CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 | Completed | USA | 0 |
| NCT01948141 | Phase II | Nintedanib | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | Completed | USA | 0 |
| NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | FRA | ESP | DEU | CHE | 2 |
| NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
| NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | ROU | POL | ITA | BGR | 0 |
| NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | DNK | 0 |
| NCT02403895 | Phase II | Vistusertib Paclitaxel | AZD2014 and Weekly Paclitaxel in Squamous NSCLC | Terminated | USA | ESP | DEU | 0 |
| NCT02417701 | Phase II | Sapanisertib | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | Completed | USA | 0 |
| NCT02443337 | Phase II | Necitumumab LY3023414 | A Study of LY3023414 and Necitumumab in Squamous Lung Cancer | Terminated | USA | 0 |
| NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT02513563 | Phase II | Carboplatin + Paclitaxel Adavosertib | AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | Completed | USA | 0 |
| NCT02536495 | Phase Ib/II | Docetaxel Selinexor | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | Withdrawn | 0 | |
| NCT02779751 | Phase II | Abemaciclib + Pembrolizumab Abemaciclib + Anastrozole + Nivolumab Abemaciclib + Anastrozole | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | Active, not recruiting | USA | TUR | ITA | FRA | ESP | BEL | 1 |
| NCT02785913 | Phase II | Taselisib | Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | Completed | USA | CAN | 0 |
| NCT02785939 | Phase II | Palbociclib | Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | Completed | USA | 0 |
| NCT02785952 | Phase III | Nivolumab Ipilimumab + Nivolumab | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Active, not recruiting | USA | CAN | 0 |
| NCT02817633 | Phase I | Cobolimab Cobolimab + Dostarlimab-gxly + TSR-033 Cisplatin + Cobolimab + Dostarlimab-gxly + Pemetrexed Disodium Cobolimab + Dostarlimab-gxly Cobolimab + Nivolumab Cobolimab + Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Active, not recruiting | USA | ESP | 1 |
| NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
| NCT02924233 | Phase Ib/II | Nivolumab + SYM004 Nivolumab | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | Withdrawn | 0 | |
| NCT03065062 | Phase I | Gedatolisib + Palbociclib | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | Recruiting | USA | 0 |
| NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
| NCT03157089 | Phase II | Afatinib + Pembrolizumab | Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO) | Completed | USA | TUR | FRA | ESP | 1 |
| NCT03178552 | Phase II | Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 13 |
| NCT03212469 | Phase Ib/II | Durvalumab + Tremelimumab | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) | Completed | FRA | 0 |
| NCT03215706 | Phase III | Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) | Completed | USA | ROU | POL | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 5 |
| NCT03234712 | Phase I | ABBV-321 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Completed | USA | ISR | AUS | 0 |
| NCT03260491 | Phase I | Patritumab deruxtecan | U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | Recruiting | USA | NLD | ESP | 3 |
| NCT03261947 | Phase II | Simurosertib | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |
| NCT03267316 | Phase Ib/II | Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) | Completed | SWE | NOR | NLD | LVA | LTU | EST | ESP | DNK | DEU | BEL | AUT | 0 |
| NCT03293680 | Phase II | Pembrolizumab | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | Completed | ESP | 0 |
| NCT03377556 | Phase II | Talazoparib | Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
| NCT03409614 | Phase III | Cemiplimab + Ipilimumab Cemiplimab | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Completed | USA | TUR | SVK | ROU | POL | LTU | ITA | IRL | GRC | FRA | AUT | 7 |
| NCT03441100 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin IMA202 | TCR-engineered T Cells in NSCLC and HCC Patients | Completed | USA | DEU | 0 |
| NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
| NCT03486730 | Phase Ib/II | BT1718 | BT1718 in Patients With Advanced Solid Tumours. | Completed | GBR | 0 |
| NCT03496766 | Phase II | Tipifarnib | Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS | Terminated | ESP | 0 |
| NCT03526887 | Phase II | Pembrolizumab | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) | Completed | ESP | 0 |
| NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
| NCT03574753 | Phase II | Telisotuzumab vedotin | Lung-MAP S1400K: c-MET Positive | Completed | USA | 0 |
| NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
| NCT03823625 | Phase II | Ipilimumab + Nivolumab Carboplatin + Gemcitabine + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT) | Unknown status | ITA | 0 |
| NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
| NCT03970746 | Phase Ib/II | PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | Active, not recruiting | POL | NLD | FRA | DEU | BEL | 0 |
| NCT03975114 | Phase II | Durvalumab + Tremelimumab Durvalumab | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) | Unknown status | ITA | 0 |
| NCT03976362 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Olaparib + Pembrolizumab | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | Active, not recruiting | USA | TUR | ROU | POL | NZL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 6 |
| NCT03976375 | Phase III | Lenvatinib Lenvatinib + Pembrolizumab Docetaxel | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | Completed | USA | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | AUS | ARG | 6 |
| NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
| NCT04033354 | Phase III | Carboplatin + Nab-paclitaxel + Serplulimab Carboplatin + Nab-paclitaxel | A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC | Unknown status | USA | TUR | POL | 4 |
| NCT04043195 | Phase Ib/II | Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) | Active, not recruiting | USA | 0 |
| NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
| NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
| NCT04149691 | Phase I | CPL304110 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Recruiting | POL | 0 |
| NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Terminated | USA | SVK | AUS | 2 |
| NCT04262856 | Phase II | AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) | Completed | USA | CAN | AUS | 4 |
| NCT04266730 | Phase I | PANDA-VAC + Pembrolizumab + Poly ICLC | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) | Not yet recruiting | USA | 0 |
| NCT04350463 | Phase II | CC-90011 + Nivolumab | A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers | Completed | USA | POL | ITA | GBR | FRA | ESP | 0 |
| NCT04357873 | Phase II | Pembrolizumab + Vorinostat | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq) | Completed | FRA | 0 |
| NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
| NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
| NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
| NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
| NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
| NCT04496674 | Phase Ib/II | CC-1 + Tocilizumab | Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung | Terminated | DEU | 0 |
| NCT04497584 | Phase II | Afatinib + Prednisone | Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC | Active, not recruiting | USA | 0 |
| NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT04748419 | Phase Ib/II | Durvalumab | Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab | Active, not recruiting | USA | 0 |
| NCT04758949 | Phase II | Nivolumab FL-101 + Nivolumab FL-101 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Withdrawn | 0 | |
| NCT04822298 | Phase I | AMG 160 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Terminated | USA | AUT | AUS | 0 |
| NCT04878484 | Phase I | TCRT-ESO-A2 | Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors | Withdrawn | 0 | |
| NCT04908111 | Phase Ib/II | MVA-MAGEA3 ChAdOx1-MAGEA3-NYESO | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | Suspended | GBR | 0 |
| NCT04939610 | Phase Ib/II | 177Lu-FAP-2286 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) | Recruiting | USA | CAN | AUS | 0 |
| NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Terminated | USA | 0 |
| NCT04956692 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | Active, not recruiting | USA | TUR | ROU | POL | HUN | FRA | ESP | BRA | 8 |
| NCT04991025 | Phase II | Certolizumab pegol + Cisplatin + Gemcitabine + Nivolumab Certolizumab pegol + Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Certolizumab pegol + Gemcitabine + Nivolumab Carboplatin + Certolizumab pegol + Nivolumab + Pemetrexed Disodium | Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | Recruiting | USA | 0 |
| NCT04995523 | Phase Ib/II | AZD2936 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01) | Recruiting | USA | NLD | GBR | FRA | ESP | DNK | BRA | BEL | AUS | 9 |
| NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
| NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | IRL | ESP | CAN | AUS | 2 |
| NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
| NCT05120271 | Phase Ib/II | BOXR1030 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) | Active, not recruiting | USA | GBR | 0 |
| NCT05123482 | Phase Ib/II | AZD2936 + AZD8205 AZD2936 + AZD8205 + Saruparib AZD8205 AZD8205 + Saruparib AZD8205 + AZD9574 AZD2936 + AZD8205 + AZD9574 | A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies | Recruiting | USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS | 5 |
| NCT05127590 | Phase Ib/II | Pembrolizumab + RBN-2397 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | Unknown status | USA | ISR | GBR | ESP | 0 |
| NCT05170204 | Phase III | Durvalumab Alectinib | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (HORIZON 1) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 13 |
| NCT05180474 | Phase Ib/II | GEN1047 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | BEL | 0 |
| NCT05194072 | Phase I | SGN-B7H4V | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Terminated | USA | GBR | ESP | DEU | CAN | 0 |
| NCT05267470 | Phase I | Bemarituzumab Bemarituzumab + Docetaxel | A Study of Bemarituzumab Monotherapy and Docetaxel Combination in Participants With Squamous Non-small-cell Lung Cancer (SqNSCLC) With Fibroblast Growth Factor Receptor Isoform 2b (FGFR2b) Overexpression (FORTITUDE-201) | Terminated | USA | POL | FRA | ESP | BEL | 3 |
| NCT05275673 | Phase II | Sapanisertib | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
| NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
| NCT05397093 | Phase I | ITIL-306 | ITIL-306 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT05557591 | Phase II | Cemiplimab BNT116 + Cemiplimab | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | Active, not recruiting | USA | TUR | ESP | DEU | 3 |
| NCT05584709 | Phase I | STI-6129 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
| NCT05607108 | Phase II | ZEN-3694 | A Study of ZEN003694 in People With Squamous Cell Lung Cancer | Recruiting | USA | 0 |
| NCT05613413 | Phase II | Cabozantinib + Pembrolizumab | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127) | Recruiting | USA | 0 |
| NCT05676749 | Phase I | Aldesleukin + C-TIL051 + Pembrolizumab | C-TIL051 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT05704634 | Phase I | Cemiplimab + Sarilumab | A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. | Active, not recruiting | USA | 0 |
| NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
| NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Terminated | USA | 0 |
| NCT05800015 | Phase II | Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | TUR | ISR | CAN | AUS | 5 |
| NCT05860296 | Phase Ib/II | Pembrolizumab + SLC-391 | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | Recruiting | USA | CAN | 0 |
| NCT05865990 | Phase II | Patritumab deruxtecan | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) | Active, not recruiting | ESP | AUT | 0 |
| NCT05873686 | Phase I | eCF506 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Recruiting | USA | GBR | 0 |
| NCT05879484 | Phase Ib/II | DS-3201b + Pembrolizumab | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | Withdrawn | USA | 0 |
| NCT05899608 | Phase III | Pembrolizumab Ivonescimab | Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients | Recruiting | USA | SWE | POL | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CAN | BEL | 4 |
| NCT05910827 | Phase Ib/II | Cetuximab + Docetaxel + HMBD-001 Docetaxel + HMBD-001 | Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers | Recruiting | AUS | 4 |
| NCT05948865 | Phase I | CPO301 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
| NCT06003075 | Phase II | Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Gemcitabine + Nivolumab | Induction Chemo-Nivo in Unresectable Stage III NSCLC | Terminated | USA | 0 |
| NCT06014658 | Phase I | MBRC-101 | Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
| NCT06225427 | Phase I | Gilteritinib | Gilteritinib for the Treatment of ALK NSCLC | Recruiting | USA | 0 |
| NCT06312137 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (TroFuse-019) | Recruiting | USA | TUR | ROU | POL | NZL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT06422143 | Phase III | Pembrolizumab + SKB264 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUT | ARG | 9 |
| NCT06427941 | Phase I | BGB-B2033 BGB-B2033 + Tislelizumab | A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | NZL | 2 |
| NCT06463665 | Phase II | Cisplatin + GL-ONC1 + Nivolumab + Pemetrexed Disodium Cisplatin + GL-ONC1 + Nab-paclitaxel + Nivolumab Cisplatin + GL-ONC1 + Nivolumab + Paclitaxel Carboplatin + GL-ONC1 + Nivolumab + Pemetrexed Disodium Docetaxel Cemiplimab + Cisplatin + GL-ONC1 + Paclitaxel Carboplatin + Cemiplimab + GL-ONC1 + Pemetrexed Disodium Carboplatin + Cemiplimab + GL-ONC1 + Nab-paclitaxel Carboplatin + Cemiplimab + GL-ONC1 + Paclitaxel Atezolizumab + Carboplatin + GL-ONC1 + Nab-paclitaxel Atezolizumab + Carboplatin + GL-ONC1 + Paclitaxel Cemiplimab + Cisplatin + GL-ONC1 + Pemetrexed Disodium Cemiplimab + Cisplatin + GL-ONC1 + Nab-paclitaxel Atezolizumab + Cisplatin + GL-ONC1 + Pemetrexed Disodium Atezolizumab + Cisplatin + GL-ONC1 + Nab-paclitaxel Atezolizumab + Cisplatin + GL-ONC1 + Paclitaxel Atezolizumab + Carboplatin + GL-ONC1 + Pemetrexed Disodium Carboplatin + Durvalumab + GL-ONC1 + Pemetrexed Disodium Carboplatin + Durvalumab + GL-ONC1 + Nab-paclitaxel Carboplatin + Durvalumab + GL-ONC1 + Paclitaxel Cisplatin + Durvalumab + GL-ONC1 + Pemetrexed Disodium Cisplatin + Durvalumab + GL-ONC1 + Nab-paclitaxel Cisplatin + Durvalumab + GL-ONC1 + Paclitaxel Cisplatin + GL-ONC1 + Paclitaxel + Pembrolizumab Carboplatin + GL-ONC1 + Pembrolizumab + Pemetrexed Disodium Carboplatin + GL-ONC1 + Nab-paclitaxel + Pembrolizumab Carboplatin + GL-ONC1 + Paclitaxel + Pembrolizumab Carboplatin + GL-ONC1 + Nab-paclitaxel + Nivolumab Carboplatin + GL-ONC1 + Nivolumab + Paclitaxel Cisplatin + GL-ONC1 + Pembrolizumab + Pemetrexed Disodium Cisplatin + GL-ONC1 + Nab-paclitaxel + Pembrolizumab | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25)) | Recruiting | USA | 0 |
| NCT06472245 | Phase III | OSE 2101 Docetaxel | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) | Recruiting | USA | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BEL | 1 |
| NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT06644768 | Phase Ib/II | Pembrolizumab DS-3201b + Pembrolizumab | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Recruiting | USA | BRA | ARG | 3 |
| NCT06692738 | Phase III | AZD2936 + Carboplatin + Nab-paclitaxel AZD2936 + Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
| NCT06747585 | Phase Ib/II | ALE.P02 | A Study to Investigate ALE.P02 As Monotherapy in Adult Patients with Selected CLDN1+ Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 4 |
| NCT06767514 | Phase III | Pembrolizumab Ivonescimab | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7) | Recruiting | USA | TUR | ROU | POL | ITA | GRC | FRA | ESP | DEU | CAN | 3 |
| NCT06789172 | Phase I | OKN4395 + Pembrolizumab OKN4395 Famotidine + OKN4395 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (INVOKE) | Recruiting | USA | GBR | AUS | 0 |
| NCT06858813 | Phase I | ABBV-324 Lenvatinib | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | Recruiting | USA | ISR | ESP | 3 |
| NCT06996782 | Phase Ib/II | AZD2936 + Cisplatin + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium + Ramucirumab AZD2936 + Carboplatin + Paclitaxel AZD2936 + Carboplatin + Nab-paclitaxel + Ramucirumab AZD2936 + Carboplatin + Nab-paclitaxel AZD2936 + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium + Ramucirumab AB248 + AZD2936 AZD2936 + Carboplatin + Paclitaxel + Ramucirumab | A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (ALTAIR) | Not yet recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | BRA | BEL | 10 |
| NCT07038915 | Phase II | Ivonescimab + Tiragolumab | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 | Withdrawn | 0 | |
| NCT07073183 | Phase I | CV09070101 | Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) | Not yet recruiting | USA | FRA | ESP | 0 |
| NCT07109726 | Phase Ib/II | TER-2013 Fulvestrant + TER-2013 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Recruiting | USA | 1 |
| NCT07182149 | Phase I | NRM-823 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Recruiting | USA | 0 |
| NCT07217171 | Phase I | EVOLVE104 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Recruiting | USA | 0 |
| NCT07217301 | Phase III | IBI363 Docetaxel | IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed (MarsLight-11) | Not yet recruiting | USA | 1 |